Skip to content
Screener

Nuvation Bio NUVB Q3 2025 earnings

Reported November 3, 2025 · After market close

Revenue$13.1MMiss by $23.7M
EPS-$0.16Beat by $0.01
Revenue estimate$36.8M
EPS estimate-$0.17

Next report

Nov 2, 2026 (in a month)
Revenue estimate$35.3M
EPS estimate-$0.12

Financials

Q3 2025

Income statement

See full
Revenue$13.1M+1,705%
Gross profit$9.8M+1,340%
Operating income-$56.4M-17.3%
Net income-$55.8M-35.4%
EPS (diluted)-$0.16-6.7%

Balance sheet

See full
Cash & equivalents$98.9M+229%
Total debt$57.5M+414%
Total equity$325.9M-35.2%
Total assets$601.6M+5.2%

Cash flow

See full
Operating cash flow-$52.9M-70.1%
CapEx$7.7M+28,793%
Free cash flow-$60.6M-95.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.27B+126%
Enterprise value$1.23B+126%
P/S47.3×-212×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-871%-428pp
Net margin-813.1%-400pp
FCF margin-740.2%-338pp

Returns & leverage

See full
Return on equity-52.5%-16.3pp
Debt / equity0.2×+0.2×
Current ratio8.5×-1.1×

Segments

By product

See full
Product Revenue$7.7M—
License$5.4M+642%
Research And Development Service Revenue$1.9M+161%
Royalty Revenue$300.0K—

FAQ

When did Nuvation Bio report Q3 2025 earnings?
Nuvation Bio (NUVB) reported Q3 2025 earnings on November 3, 2025 after market close.
What were Nuvation Bio's Q3 2025 revenue and EPS?
Nuvation Bio reported revenue of $13.1M and eps of $-0.16 for Q3 2025.
Did Nuvation Bio beat estimates in Q3 2025?
Revenue missed the consensus estimate of $36.8M by $23.7M. EPS beat the consensus estimate of $-0.17 by $0.01.
How did Nuvation Bio's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1704.7% from $727.0K a year earlier and eps declined 6.7% from $-0.15.
Where can I find Nuvation Bio's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-262576) and the 10-Q periodic report (0001193125-25-262605) directly on SEC EDGAR. The filing index links above go to sec.gov.